Le Lézard
Classified in: Health
Subject: PDT

ThermoGenesis Corp® Completes Construction and Qualification of In-House Clean Room for Assembly of All X-Seriestm Cell Processing Disposables


RANCHO CORDOVA, Calif., Jan. 21, 2019 /PRNewswire/ -- ThermoGenesis Corp, a private corporation owned by Cesca Therapeutics (Nasdaq: KOOL), and a market leader in automated cellular processing and autologous cell therapies for regenerative medicine, today announced the construction and qualification of a new Class 100,000, GMP compliant assembly facility to manufacture all X-Series cell processing disposables. 

Haihong Zhu, President of ThermoGenesis, stated, "Now that we have completed the transfer of assembly of both our cell processing disposables and automated Control Module and Docking Station devices from third-party vendors to our in-house facility in Rancho Cordova, we have better control over our supply chain and are able to provide even higher quality products and improved customer service. Equally important, ThermoGenesis is now better equipped to scale its manufacturing rate to keep pace with the rising demand for the X-Series 'closed system' automated cell processing products." These products include:

About ThermoGenesis Corp.     
ThermoGenesis develops, commercializes and markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company has developed an automated, functionally-closed CAR-TXpresstm platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For additional information, please visit: www.thermogenesis.com.

About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is a market leader in cell processing technologies and autologous cell therapies for regenerative medicine. For more information, visit: www.cescatherapeutics.com.

Company Contact:
ThermoGenesis Corp
Wendy Samford
916-858-5191
[email protected]  

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]

SOURCE Cesca Therapeutics Inc.


These press releases may also interest you

at 16:42
Grifols 2023 Annual Report on Form 20-F filed with the SEC
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
FDA Roundup: April 19, 2024
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor eyes SEIU-CUPE award for Ontario health care members
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

at 15:55
Valley Mountain Regional Center Provides Notice Following Data Security Incident
Valley Mountain Regional Center ("VMRC") experienced a data security incident that involved personal and / or protected health information belonging to certain current and former patients and has provided notice of this incident to impacted...

More news about Health...


News published on and distributed by: